Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.05 USD
-0.09 (-7.89%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.05 USD
-0.09 (-7.89%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Zacks News
Adicet Bio, Inc. (ACET) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adicet Bio, Inc. (ACET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Adicet Bio (ACET)
by Zacks Equity Research
Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Strong Sell Stocks for May 28th
by Zacks Equity Research
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher
by Zacks Equity Research
Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.
New Strong Sell Stocks for April 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for April 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for March 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for November 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Weakness Seen in Aceto Corporation (ACET) Estimates: Should You Stay Away?
by Zacks Equity Research
Aceto Corporation (ACET) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
by Zacks Equity Research
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
5 Stocks to Bet on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Should You Get Rid of INC Research (INCR) Now?
by Zacks Equity Research
INC Research (INCR) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Investing Podcast Highlights: Snapchat, Israeli Tech Companies, Movie Stocks, and More
by Ryan McQueeney
Investing Podcast Highlights: Snapchat, Israeli Tech Companies, Movie Stocks, and More
Top Ranked Value Stocks to Buy for March 6th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, March 6th:
Should You Get Rid of Ensign Group (ENSG) Now?
by Zacks Equity Research
Ensign Group (ENSG) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Top Ranked Value Stocks to Buy for March 2nd
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, March 2nd:
3 Value Stocks on Sale
by Tracey Ryniec
Do you have the guts to buy a stock that has sold off when the market is hitting new highs?
Top Ranked Value Stocks to Buy for February 28th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, February 28th:
Top Ranked Value Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, February 27th:
Top Ranked Value Stocks to Buy for February 24th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong value characteristics for investors to consider today, February 24th: